Research applications include investigations into NAD+ metabolism, mitochondrial function, and metabolic adaptation.
From a theoretical pharmacological standpoint, combining a peptide with putative lipolytic activity (AOD 9604) with a potent triple incretin receptor agonist (retatrutide) could potentially amplify metabolic effects but this is speculative and raises the possibility of compounding adverse effects with no safety data to guide dosing or monitoring
Not for human consumption, clinical use, or therapeutic applications
If deficiency symptoms persist, consult a veterinarian
Blood 1998;92:1191-1198
This guide lays out the documented research protocol for both the 10 mg and 50 mg vials, shows the reconstitution arithmetic step by step, and gives a scannable weekly schedule, cycling framework, and realistic timeline